How should Strattera (atomoxetine) be dosed and monitored in an adult patient with ADHD and hypertension?

Strattera (Atomoxetine) in Adults with ADHD and Hypertension

Strattera can be used in adults with ADHD and hypertension, but requires careful blood pressure monitoring and dose titration to a target of 80 mg/day, with the understanding that it may cause modest increases in blood pressure (3-8 mmHg systolic, 2-14 mmHg diastolic) that are generally less problematic than stimulants.

Key Advantages in Hypertensive Patients

Atomoxetine is a reasonable first-line option for adults with ADHD and comorbid hypertension because:

• Non-stimulant profile: Unlike amphetamines and methylphenidate, atomoxetine is not a controlled substance and may have a more favorable cardiovascular profile 1
• "Around-the-clock" effects: Provides continuous symptom control without the rebound effects seen with stimulants 1
• Smaller pressor effect: While it does increase blood pressure, the effect is generally modest and comparable to stimulants 2, 3

Dosing Protocol

Initial Dosing

• Start at 40 mg/day for the first 3 days, then increase to 80 mg/day 4
• Can be given as a single morning dose or divided (40 mg BID) 5
• For patients weighing <70 kg, initial target is 0.5 mg/kg/day, then increase after minimum 3 days to target of approximately 1.2 mg/kg/day 4

Target Dosing

• 80 mg/day is the recommended target dose for most adults 4, 6, 7
• Maximum dose: 100 mg/day 4
• Critical point: Real-world data shows many patients are underdosed at ~60 mg/day, which compromises efficacy 7. Patients reaching 80 mg/day have significantly longer treatment duration (159 days vs 66 days) 6

Dose Titration Timeline

• May increase to 100 mg/day after 2-4 weeks if 80 mg is insufficient and well-tolerated 4
• Allow 4-6 weeks at target dose before judging efficacy 7, 8—effect size increases from 0.28 at 1 week to 0.52 at 26 weeks 8

Cardiovascular Monitoring Requirements

Baseline Assessment

• Blood pressure and pulse measurement 9
• Document any history of cardiovascular disease
• Note: Hypertension is NOT an absolute contraindication to atomoxetine, unlike with stimulants where it requires more caution 9

Ongoing Monitoring

• Check blood pressure and pulse at each dose adjustment 2, 10
• Quarterly monitoring once stable on maintenance dose 9
• Monitor for new-onset hypertension (BP ≥140/90 mmHg)—occurs in approximately 10% of patients on ADHD medications 2

Expected Cardiovascular Changes

• Average increases: Heart rate +3-10 bpm, systolic BP +3-8 mmHg, diastolic BP +2-14 mmHg 3
• These changes are statistically significant but clinically modest 2
• One case report of hypertensive crisis exists 11, emphasizing need for monitoring

Management Strategy for Hypertension

If Blood Pressure Increases on Atomoxetine

1. Optimize antihypertensive therapy first 12, 13, 14—the ACC/AHA guidelines recommend initiating or intensifying antihypertensive therapy rather than discontinuing ADHD medication
2. Consider dose reduction if BP elevation is significant 12, 13
3. Discontinue only if severe or uncontrolled hypertension develops 12, 14

Antihypertensive Medication Considerations

• Standard first-line agents (ACE inhibitors, ARBs, thiazide diuretics, calcium channel blockers) can be used 15, 16
• Target BP <140/90 mmHg 15
• Avoid combining atomoxetine with MAO inhibitors (contraindicated) 9

Special Considerations

CYP2D6 Poor Metabolizers

• Approximately 7% of Caucasians are poor metabolizers 4
• These patients have 10-fold higher drug exposure and 5-fold higher peak concentrations 4
• Start at 40 mg/day and titrate more slowly; maximum dose 80 mg/day 4
• Higher rate of adverse effects expected 1, 4

Dosing Flexibility

• Once-daily (QD) vs twice-daily (BID) dosing: Both are effective 5
• BID dosing (40 mg twice daily) may reduce nausea compared to 80 mg QD (16.4% vs 32.4%) 5
• Can switch between QD and BID based on tolerability without safety concerns 5

Common Pitfalls to Avoid

1. Underdosing: Stopping at 40-60 mg/day instead of reaching the 80 mg target 6, 7
2. Premature discontinuation: Judging efficacy before 4-6 weeks at target dose 7, 8
3. Inadequate BP monitoring: Failing to check BP at baseline and during titration 2, 10
4. Assuming hypertension is an absolute contraindication: It is not, unlike with stimulants where more caution is warranted 9, 12, 14

Efficacy Timeline

• Week 1: Small effect (0.28 effect size) 8
• Week 4: Moderate effect (0.45 effect size) 8
• Week 26: Larger effect (0.52 effect size overall; 0.82 in 80 mg group) 8
• Response rates continue to increase throughout 6 months of treatment 8

The key message: Atomoxetine is a viable option for adults with ADHD and hypertension, requiring systematic dose titration to 80 mg/day with regular cardiovascular monitoring, and patience for full therapeutic effect over 4-6 weeks.